These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 3607720

  • 1. Studies on tumor necrosis factor (TNF). III. Plasma disappearance curves after intramuscular, subcutaneous, intraperitoneal, and oral administration of human recombinant TNF.
    Pacini A, Maioli E, Bocci V, Pessina GP.
    Cancer Drug Deliv; 1987; 4(1):17-23. PubMed ID: 3607720
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.
    Saks S, Rosenblum M.
    Immunol Ser; 1992; 56():567-87. PubMed ID: 1550875
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies.
    Tanaka H, Kaneko T.
    Drug Metab Dispos; 1991; 19(1):200-4. PubMed ID: 1708329
    [Abstract] [Full Text] [Related]

  • 4. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS, Harrigan R, Bahn JD, Printz MA, Sugarman BJ, DeNoia E, Haughey DB, Fellows D, Maneval DC.
    Clin Ther; 2014 Feb 01; 36(2):211-24. PubMed ID: 24486335
    [Abstract] [Full Text] [Related]

  • 5. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers.
    Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, Buraglio M, Ythier A, Munafo A.
    Eur Cytokine Netw; 2001 Feb 01; 12(3):391-8. PubMed ID: 11566619
    [Abstract] [Full Text] [Related]

  • 6. Studies on tumor necrosis factor (TNF)--I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration.
    Bocci V, Pacini A, Pessina GP, Maioli E, Naldini A.
    Gen Pharmacol; 1987 Feb 01; 18(4):343-6. PubMed ID: 3609691
    [Abstract] [Full Text] [Related]

  • 7. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.
    Havell EA, Fiers W, North RJ.
    J Exp Med; 1988 Mar 01; 167(3):1067-85. PubMed ID: 3351434
    [Abstract] [Full Text] [Related]

  • 8. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
    Jablons DM, Mulé JJ, McIntosh JK, Sehgal PB, May LT, Huang CM, Rosenberg SA, Lotze MT.
    J Immunol; 1989 Mar 01; 142(5):1542-7. PubMed ID: 2783945
    [Abstract] [Full Text] [Related]

  • 9. Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer.
    Erstad BL, Barletta JF.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1236-1244. PubMed ID: 35176754
    [Abstract] [Full Text] [Related]

  • 10. Studies on tumor necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNF.
    Pessina GP, Pacini A, Bocci V, Maioli E, Naldini A.
    Lymphokine Res; 1987 Jul 22; 6(1):35-44. PubMed ID: 3821169
    [Abstract] [Full Text] [Related]

  • 11. Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF).
    Kashiwa H, Wright SC, Bonavida B.
    J Immunol; 1987 Mar 01; 138(5):1383-90. PubMed ID: 2949015
    [Abstract] [Full Text] [Related]

  • 12. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
    McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH, Davis HL.
    Mol Med; 1999 May 01; 5(5):287-300. PubMed ID: 10390545
    [Abstract] [Full Text] [Related]

  • 13. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.
    Aulitzky WE, Tilg H, Gastl G, Mull R, Flener R, Vogel W, Herold M, Berger M, Judmaier G, Huber C.
    Eur J Cancer; 1991 May 01; 27(4):462-7. PubMed ID: 1827721
    [Abstract] [Full Text] [Related]

  • 14. Relationship between lethal toxicity in oral administration and injection to mice: effect of exposure routes.
    Wang Y, Ning ZH, Tai HW, Long S, Qin WC, Su LM, Zhao YH.
    Regul Toxicol Pharmacol; 2015 Mar 01; 71(2):205-12. PubMed ID: 25558060
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing.
    Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D.
    J Rheumatol; 1993 Nov 01; 20(11):1845-9. PubMed ID: 8308768
    [Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
    Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, O'Connor JV.
    J Exp Med; 1986 Jun 01; 163(6):1433-50. PubMed ID: 3486936
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.
    Andrews JS, Berger AE, Ware CF.
    J Immunol; 1990 Apr 01; 144(7):2582-91. PubMed ID: 1969453
    [Abstract] [Full Text] [Related]

  • 20. The relative bioavailability and metabolism of bisphenol A in rats is dependent upon the route of administration.
    Pottenger LH, Domoradzki JY, Markham DA, Hansen SC, Cagen SZ, Waechter JM.
    Toxicol Sci; 2000 Mar 01; 54(1):3-18. PubMed ID: 10746927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.